GlassScriptPhysician profile
Ahmad Rashid
NPI 1538155585
$753.21
in general payments reported to CMS, 2019-2025
14 companies · $199 in 2025
The $199 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $123 · 2023: $40.55 · 2024: $150 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $389.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $176.33 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Merck Sharp & Dohme LLC | $109.32 | 2019-2025 | Zerbaxa, Recarbrio |
| Genzyme Corporation | $94.88 | 2024-2025 | |
| Inogen, INC. | $65.31 | 2025 | |
| Mylan Specialty L.P. | $64.04 | 2019-2020 | |
| Glaxosmithkline, LLC. | $51.90 | 2019-2025 | Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.60 | 2019 | |
| Alexion Pharmaceuticals, INC. | $34.64 | 2019 | |
| United Therapeutics Corporation | $22.54 | 2023 | Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $19.64 | 2024 | Glassia |
| Circassia INC. | $19.33 | 2020 | |
| Grifols USA, LLC | $18.72 | 2019 | |
| Inspire Medical Systems, INC. | $18.01 | 2023 | Inspire |
| Sunovion Pharmaceuticals INC. | $14.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmad Rashid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.